Pomalidomid

Pomalidomid

Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	9,4 h
Identifikatori
CAS broj	19171-19-8^Y
ATC kod	L04AX06 (WHO)
PubChem	CID 134780
DrugBank	DB08910^Y
ChemSpider	118785^Y
ChEBI	CHEBI:72690^Y
ChEMBL	CHEMBL43452^Y
Hemijski podaci
Formula	C13H11N3O4
Molarna masa	273,244
SMILES NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
InChI InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)^Y Key:UVSMNLNDYGZFPF-UHFFFAOYNA-N^Y

Pomalidomid je organsko jedinjenje, koje sadrži 13 atoma ugljenika i ima molekulsku masu od 273,244 Da.^{[1][2][3][4][5]}

Osobine

Osobina	Vrednost
Broj akceptora vodonika	5
Broj donora vodonika	2
Broj rotacionih veza	1
Particioni koeficijent[6] (ALogP)	-0,7
Rastvorljivost[7] (logS, log(mol/L))	-1,9
Polarna površina[8] (PSA, Å^2)	109,6

Reference

1. Gertz, M. A. (2013). „Pomalidomide and myeloma meningitis”. Leukemia & Lymphoma. 54 (4): 681—682. PMID 22917017. doi:10.3109/10428194.2012.723708. 
2. McCurdy, A. R.; Lacy, M. Q. (2013). „23730498”. Therapeutic Advances in Hematology. 4 (3): 211—216. PMC 3666447 . PMID 23730498. doi:10.1177/2040620713480155. 
3. Terpos, E.; Kanellias, N.; Christoulas, D.; Kastritis, E.; Dimopoulos, M. A. (2013). „23690693”. Oncotargets and Therapy. 6: 531—538. PMC 3656921 . PMID 23690693. doi:10.2147/OTT.S34498 . 
4. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. 
5. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. 
6. Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
7. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
8. Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

• Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803. 
• Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799. 

Spoljašnje veze

• Pomalidomide

Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja).